-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Kang Fang Biotech (09926.HK) issued an announcement. The results of the pre-set midterm analysis of the world's first bispecific antibody Idafang® (Evarisil, PD-1/VEGF) combination chemotherapy plan independently developed by the company showed that the study had reached the overall survival period of a randomized, controlled, double-blind, multicenter phase III clinical study (AK112-309/Harmoni-GI1) for first-line treatment of advanced biliary tract cancer (PD-L1 OS) The main study endpoint, with statistically significant positive results with significant clinical benefits; the study also reached all key secondary endpoints of progression-free survival (PFS) and objective response rate (ORR).

Zhitongcaijing·08/25/2026 23:49:02
Listen to the news
Zhitong Finance App News, Kang Fang Biotech (09926.HK) issued an announcement. The results of the pre-set midterm analysis of the world's first bispecific antibody Idafang® (Evarisil, PD-1/VEGF) combination chemotherapy plan independently developed by the company showed that the study had reached the overall survival period of a randomized, controlled, double-blind, multicenter phase III clinical study (AK112-309/Harmoni-GI1) for first-line treatment of advanced biliary tract cancer (PD-L1 OS) The main study endpoint, with statistically significant positive results with significant clinical benefits; the study also reached all key secondary endpoints of progression-free survival (PFS) and objective response rate (ORR).